Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. by McCann, LJ et al.
McCann et al. Pediatric Rheumatology 2014, 12:31
http://www.ped-rheum.com/content/12/1/31RESEARCH Open AccessDeveloping a provisional, international Minimal
Dataset for Juvenile Dermatomyositis: for use in
clinical practice to inform research
Liza J McCann1*, Katie Arnold2, Clarissa A Pilkington2,4, Adam M Huber5, Angelo Ravelli6, Laura Beard2,
Michael W Beresford1,7, Lucy R Wedderburn2,3,4 and the UK Juvenile Dermatomyositis Research Group (JDRG)4Abstract
Background: Juvenile dermatomyositis (JDM) is a rare but severe autoimmune inflammatory myositis of childhood.
International collaboration is essential in order to undertake clinical trials, understand the disease and improve
long-term outcome. The aim of this study was to propose from existing collaborative initiatives a preliminary
minimal dataset for JDM. This will form the basis of the future development of an international consensus-approved
minimum core dataset to be used both in clinical care and inform research, allowing integration of data between
centres.
Methods: A working group of internationally-representative JDM experts was formed to develop a provisional
minimal dataset. Clinical and laboratory variables contained within current national and international collaborative
databases of patients with idiopathic inflammatory myopathies were scrutinised. Judgements were informed by
published literature and a more detailed analysis of the Juvenile Dermatomyositis Cohort Biomarker Study and
Repository, UK and Ireland.
Results: A provisional minimal JDM dataset has been produced, with an associated glossary of definitions. The
provisional minimal dataset will request information at time of patient diagnosis and during on-going prospective
follow up. At time of patient diagnosis, information will be requested on patient demographics, diagnostic criteria
and treatments given prior to diagnosis. During on-going prospective follow-up, variables will include the presence
of active muscle or skin disease, major organ involvement or constitutional symptoms, investigations, treatment,
physician global assessments and patient reported outcome measures.
Conclusions: An internationally agreed minimal dataset has the potential to significantly enhance collaboration,
allow effective communication between groups, provide a minimal standard of care and enable analysis of the
largest possible number of JDM patients to provide a greater understanding of this disease. This preliminary dataset
can now be developed into a consensus-approved minimum core dataset and tested in a wider setting with the
aim of achieving international agreement.
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Juvenile dermatomyositis (JDM) is a severe, autoimmune,
inflammatory myositis that can cause death and major
long-term health problems [1-3]. There are major gaps
in knowledge regarding epidemiology, pathogenesis,
response to medication and long-term outcome of the
disease [4]. Although most children with JDM now sur-
vive to adulthood (5 year survival > 95%) [5], a significant
number (70-80%) have on-going disease activity [1-3].
JDM differs in many ways from myositis in adults [5]. As
JDM is rare, affecting 2–3 per million children per year
[6,7], international collaboration between paediatric and
adult JDM research groups is essential to undertake clin-
ical trials, understand the disease, and improve long-term
outcome. The first prospective randomised trial in myo-
sitis (evaluating rituximab in refractory disease) enrolling
both paediatric and adult patients through international
collaboration was recently published [8]. A collaborative
randomised trial of prednisolone, methotrexate and ciclos-
porin in JDM has recently been completed [9]. Aside from
these, there remains a significant paucity of robust evi-
dence regarding therapeutic interventions for JDM in the
paediatric and adolescent age group.
To date, two parallel processes have led to the develop-
ment of two ‘core sets’ for JDM in America (via the Inter-
national Myositis and Clinical Studies [IMACS] group)
[10-12] and in Europe (via Paediatric Rheumatology Inter-
national Trials Organisation, PRINTO) [13-15]. These core
sets overlap but differ in important details and lack inter-
national agreement. They were developed with the main
purpose for clinical trials and therefore can be difficult to
use in routine clinical practice due to time constraints.
Disease specific registries, particularly when linked to a
biobank of biological specimens, can be powerful tools
enabling epidemiological research, identification of risk
factors to develop disease (such as gene-environment
interaction) and identification of patients for clinical tri-
als [16]. They can also drive a minimal standard of care
by encouraging capture of important variables for dis-
ease monitoring within clinical use. In addition, regis-
tries have the potential of providing a platform for the
development of robust pharmacosurveillance and post-
marketing drug safety monitoring, exemplified by the
Childhood Arthritis and Rheumatology Research Alliance
(CARRA) Consolidated Safety Registry (CoRe) [17]. The
Juvenile Dermatomyositis Cohort Biomarker Study and
Repository, UK and Ireland (JDCBS) provides a large pro-
spective collection of juvenile idiopathic inflammatory
myopathies (currently >430 patients) with a repository of
linked biological and serological specimens [18]. In 2010,
CARRA initiated a multi-centre observational registry in
the United States to create a clinical database for the
major rheumatic diseases, [19] which has reported data
from 384 JDM patients enrolled within the first 2 years[20]. In 2008, a European initiative was taken to develop a
web-based registry for adult myositis patients, Euromyosi-
tis [16], which is currently being expanded to include JDM
patients through collaboration with the UK Juvenile
Dermatomyositis Research Group (JDRG) [18].
The concept underpinning disease-specific registries is
a user-friendly, accessible database that can be useful in
clinical practice and encourages data-entry for research
purposes. In order to achieve this, databases need to col-
lect important information that helps to define disease
outcome and if possible inform treatment, but not be so
extensive that it is too time-consuming. Ideally, it should
be linked to the patient record to avoid duplication [16]
and yet be protected so that patients are not identifiable
within a secure web-based system when data are ex-
tracted for research purposes.
Currently, existing databases within JDCBS, CARRA
and Euromyositis have dataset parameters that are par-
tially overlapping but use different data items. Analysis
of information held within these individual data collec-
tions has led to a greater understanding of the disease,
resulting in numerous publications on JDM [18,20].
However, many important questions remain unanswered
and depend on analysis of larger numbers of patients
than are currently available in individual collections. To
address this, this present study aimed to scrutinize the
existing collaborative datasets to propose a common
minimal core data set comprising clinical, laboratory
and patient/parent reported measures for patients with
JDM. We aimed for such a core data set to be clinically
practical, incorporate key variables that allow accurate
assessment of disease activity and measure change (such
as response to treatment), and for the data set to be used
in the development of future clinical trials in JDM. Such
a common dataset, could form the basis for a future
consensus-driven, internationally approved minimum
core dataset that can be rapidly incorporated into na-
tional and international collaborative efforts, including
existing prospective databases, and be available for use
in randomised controlled trials and for treatment /
protocol comparisons in cohort studies.
Methods
A group of five JDM experts from the UK, Italy and
Canada (LM,CP,LW,AH,AR) representative of the major
groups studying JDM and maintaining databases (CARRA,
UK JDCBS, PRINTO) formed a working group which
aimed to produce a provisional minimal dataset for
JDM [21].
A literature search, carried out by one author (LM),
aimed to identify any variables potentially missing from
current database collections but used within validated
research tools. The search (EMBASE, MEDLINE, Sep-
tember 2012; main search terms ‘dermatomyositis’ OR
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‘dataset’ or ‘consensus’ or ‘core set) identified 272 publica-
tions. Articles containing variables used within published
‘core sets’ for research purposes (PRINTO/IMACS) and
variables used within articles describing disease classifi-
cation, diagnostic criteria, clinical characteristics, disease
monitoring, outcome assessment/response to treatment
or definition of inactive disease were listed for initial con-
sideration and presented to the group.
A detailed analysis of variables from three existing
large registries of patients with Idiopathic Inflammatory
Myopathies (IIM), namely JDCBS (www.juvenilederma-
tomyositis.org.uk), CARRA (www.carragroup.org), and
Euromyositis (www.euromyositis.eu), as well as those
used in a Paediatric Rheumatology INternational Trials
Organisation (PRINTO) coordinated retrospective study
analyzing 490 JDM patients [1], was undertaken. Each
variable common to at least two databases was listed
and scrutinized for usefulness within its clinical context
and for research studies by e-mail and teleconference
discussion within the expert group [21]. Variables were
only included in the provisional dataset when 100% of
group members agreed that they were potentially im-
portant for clinical use and/or future research.
To inform discussion, a separate detailed analysis of
the UK JDCBS database was carried out in July 2011 to
determine the number of times that variables were com-
pleted accurately. The JDCBS had ethical approval from
the North Yorkshire Multi-Centre Research Ethics Com-
mittee and this study was also approved by the Steering
Committee of the UK JDM Cohort Study. At this time
the JDCBS had recruited 285 children with sufficient
data available for analysis on 275 cases [18] of which 175
(63.3%) had been recruited prospectively within 12 months
of onset. Any variable completed <50% of the time was
scrutinized and discussed within the expert group to de-
termine importance of inclusion versus reliability of com-
pletion and to see if questions could be asked in a more
steadfast way to encourage completion.
Definitions of variables used by the individual databases
were reviewed. Those used within the Euromyositis data-
base were modified for paediatric use. A combination of
these definitions, with the aid of agreed and published de-
scriptions of cutaneous manifestations of IIM [22], were
used to form a glossary/definition of variables.
Results
Analysis of the four datasets (JDCBS, CARRA, Euromyosi-
tis, PRINTO) showed that 19 variables were common to all
four datasets, 16 were common to three datasets, and 24
were common to two datasets (Table 1). Although only one
database (JDCBS) included data on the use of physiother-
apy, this variable was retained within the treatment listing
as it was felt to be important by all JDM experts. Likewise,malignancy was retained as a variable, despite being re-
corded by Euromyositis alone. Therefore a total of 61 vari-
ables were scrutinized for potential inclusion. An additional
29 variables were identified as only being in one of the four
datasets and excluded from further consideration at this
stage. Cross-referencing of variables listed from the litera-
ture search and included within research tools such as the
Myositis Disease Activity Assessment (MDAA) and Disease
Activity Score (DAS) [15] was carried out to ensure that
members of the working groups were satisfied that all vari-
ables important for clinical use were included. This process
informed discussion but did not lead to the inclusion of any
additional variables.
All registries or data collections included patient
demographics, date of onset of symptoms, date of diag-
nosis and growth indicators. They all included diag-
nostic indicators of JDM, including evidence of a
characteristic skin rash, proximal muscle weakness,
muscle enzyme elevation, electromyogram (EMG) and
muscle biopsy evidence of myositis. There were some
differences in how these data were documented, par-
ticularly when comparing adult and paediatric regis-
tries. All databases asked about the presence of skin
ulceration, calcinosis, arthritis and cardiac/respiratory
involvement although there were differences in how
the questions were asked and data presented. All data-
bases asked for medication history.
Two databases asked about neurological involvement.
Capture of systemic symptoms (weight loss, fatigue,
myalgia, irritability) varied between databases. There
were differences in how disease activity over time was
monitored, although the majority of databases included
patient/parent Visual Analogue Scale (VAS), a Health
Assessment Questionnaire (CHAQ/HAQ), physician
global VAS, and a measure of muscle strength; either
the Childhood Myositis Assessment Scale (CMAS) and/or
Manual Muscle Testing (MMT) [23]. The PRINTO study
used the Disease Activity Score (DAS) whereas Euromyosi-
tis included the Myositis Intention to Treat Activity Index
(MITAX) and the Myositis Disease Activity Assessment
Visual Analogue Scales (MYOACT) [23].
The presence of Raynaud’s phenomenon was retained
due to the potential significance of progression of
childhood onset myositis into scleroderma or myositis/
scleroderma overlap in adult life [24]. The presence of
mechanics hands and malignancy were each retained des-
pite being infrequent in paediatrics, in order to compare
with adult datasets.
Scrutiny of the UK JDCBS database, which included rou-
tine collection of 54 out of a total of 61 possible variables in
the provisional minimal database, showed that at baseline,
8/54 (15%) variables were completed in <50% of patients.
Specific concerns were noted with completion of family
history, Childhood Health Assessment Questionnaire,
Table 1 Variables common to more than two datasets, considered for inclusion in provisional minimal dataset
Variables common to four datasets (n = 19) Variables common to three datasets (n = 16) Variables common to two datasets (n = 24)
Date of birth and patient code Patient name Postcode
Gender Patient centre Death
Ethnicity Diagnosis date Fatigue due to JDM
Family history JDM rash Distribution of rash
Onset date Skin erythema Abdominal pain due to JDM
Height/Weight MRI consistent with JDM at diagnosis Neurological involvement
Symmetrical muscle weakness CMAS Weight loss due to JDM
Gottron’s or heliotrope rash Gottron’s sign Alopecia due to JDM
Skin ulcers Shawl sign Nail-fold changes
Dysphagia or dysphonia Gastro-intestinal disease / ulceration due to JDM Dysphagia
Calcinosis Fever due to JDM Dysphonia
Cardiac involvement Abnormal pulmonary function tests Respiratory symptoms
Arthritis Contractures Myalgia
Interstitial lung disease Lipodystrophy Eye disease (glaucoma/cataract)
MMT8 Autoantibody data (more than ANA) Raynaud’s
Muscle enzymes elevated Physician global assessment Parental Visual Analogue Scale (VAS)
EMG changes consistent with JDM at diagnosis Pain VAS
Muscle biopsy consistent with JDM CHAQ
Medication history MITAX/MYOACT
Hospitalisation since last visit
School absence
Other significant diagnosis
Sporting activities
Pubertal delay
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of disease activity, pain visual analogue score, as well as
nail-fold capillary changes, lipodystrophy and Raynaud’s
phenomenon. Analysis of completion rates for two of
these variables (nail-fold changes and Raynaud’s) could
have been confounded by the fact that they were not in-
cluded in the original data collection forms, but added
at a later date. With prospective collection, parameters
performing poorly (completed in <50% patients) were
MRI, muscle biopsy, antibody and pulmonary function
test results. Discussion within the expert group con-
firmed the importance of these parameters but led to re-
phrasing of questions to support future enhanced data
completion. For example, the question ‘pulmonary in-
volvement due to myositis’ was favoured as opposed to
asking clinicians to document the results of pulmonary
function tests.
A provisional minimal dataset was therefore estab-
lished from the existing collaborative datasets for use in
clinics and inform clinical trials and research studies.
This provisional dataset was then configured into user-friendly forms (Figures 1, 2, 3, 4 and 5) and organized
into ten domains. Three of these domains (demographic
data, diagnostic data and treatment prior to diagnosis)
are questions that would be asked at first presentation
only (Figures 1 and 2). The remaining seven domains
(growth, clinical features, ongoing follow up, physician
reported outcome measures, patient/parent reported
outcome measures, investigations, treatment) are rele-
vant for every patient visit (Figures 3, 4 and 5). A gloss-
ary for form A (Figures 1 and 2) and form B (Figures 3,
4 and 5) are available as Additional file 1 (Form A:
provisional definitions, Form B: provisional definitions).
Our working group includes a member of the Euromyo-
sitis Steering Committee and in collaboration with the
Euromyositis Research Group, we have used the provisional
dataset as a platform to create a paediatric-specific webpage
for the Euromyositis database, ensuring compatibility with
the web-based system used to collect data on adult-onset
idiopathic inflammatory (www.euromyositis.eu).
Further work will develop this preliminary dataset
into a consensus-approved minimum core dataset, tested
Provisional JDM Minimal Dataset, Form A - first data entry only
Instructions on use / definitions available as supplementary material. 
For variables that are not available at time of data entry, but will be available at a later date, mark ‘not available’, (so that 
they can be chased and added at a later date).
For variables that have not been examined / investigated, mark ‘not recorded’. 
Patient ID Number* Patient Name*
Patient Consultant /
Lead Clinician? *
Patient Hospital*
and country
Information to be completed or details omitted pending local ethics and legal considerations
Date of form 
completion
A. Demographic Data
DOB*: Gender: Male / Female
Ethnicity (Details to be further defined by 
consensus)
Family History (1st degree relative)
1. Neuromuscular 
disease Yes No Not Known Not Available
If yes, state disease_____________________________________________
2. Autoimmune disease Yes No Not Known Not Available
If yes, state disease _____________________________________________
B. Diagnostic Data
For definitions please refer to supplementary sheet
1. Disease type: JDM
JPM
JDM overlap with: Arthritis / Lupus / Scleroderma / Sjogren’s / MCTD (RNP +ve)
Amyopathic JDM
Incomplete DM
Inclusion body 
myositis (IBM)
Mark all overlap features that apply
2. Date of first symptom (mm/yyyy) _____/_____ 
3. Date of diagnosis (mm/yyyy) _____/_____
4. Diagnostic Clinical Criteria 
Symmetrical proximal muscle weakness
Yes No Not Available
(at time of data 
entry but can be 
completed later)
Not Done
Dermatological features of JDM:
Heliotrope rash Yes No Not Available Not Done
Gottron's papules or Gottron's sign Yes No Not Available Not Done
Nailfold capillary changes Yes No Not Available Not Done
Other characteristic JDM rash Yes No Not Available Not Done
Figure 1 Provisional JDM minimal dataset Form A (first data entry only), page 1 –demographic and diagnostic data.
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Discussion
International collaboration among myositis experts within
IMACS and PRINTO has led to the development of two
core set measures for JDM [10-15]. These are important
tools predominantly designed for research and clinical trials.
Time constraints limit the use of these in routine clinical
practice. However, the tools capture important variables that
measure disease activity and damage in JDM. In this study
we have attempted to capture these individual variableswithin a provisional minimal dataset with the aim of produ-
cing a platform for recording important information within
routine clinical practice, and providing a minimum standard
of care for JDM. This will have the added benefit of being
able to be used to inform future research and will therefore
compliment the existing IMACS/PRINTO core sets.
Our group has scrutinized variables collected within four
existing databases, in addition to variables used within
established research tools and published literature, to form
a provisional minimal dataset for JDM. Further develop-
ment is now needed through a formal consensus-driven
process with the aim of ultimately achieving a unified
Muscle biopsy evidence of myositis: Yes No Not Available Not Done
If yes, date of biopsy (dd/mm/yyyy): _____________________
Elevation of muscle 
enzyme: CK Yes No Not Available Not Done
LDH Yes No Not Available Not Done
Adolase Yes No Not Available Not Done
AST/SGOT Yes No Not Available Not Done
ALT/SGPT Yes No Not Available Not Done
EMG changes of myopathy Yes No Not Available Not Done
MRI Changes of Myositis Yes No Not Available Not Done
Auto-antibodies positive: ANA Yes No Not Available Not Done
Anti-p155/140 Yes No Not Available Not Done
Anti-p140 Yes No Not Available Not Done
Anti-Jo1 Yes No Not Available Not Done
Anti-ARS Yes No Not Available Not Done
Anti-PL12 Yes No Not Available Not Done
Anti-PL7 Yes No Not Available Not Done
Anti-EJ Yes No Not Available Not Done
Anti-OJ Yes No Not Available Not Done
Anti-Mi2 Yes No Not Available Not Done
Anti-SRP Yes No Not Available Not Done
Anti-U1-RNP Yes No Not Available Not Done
Anti-U3-RNP Yes No Not Available Not Done
Anti-PM-Scl 75 Yes No Not Available Not Done
Anti-PM-Scl 100 Yes No Not Available Not Done
Anti-Ro52 Yes No Not Available Not Done
Anti-Ro60 Yes No Not Available Not Done
Anti-La Yes No Not Available Not Done
Anti-Ku Yes No Not Available Not Done
Anti-Topo Yes No Not Available Not Done
Anti-SAE Yes No Not Available Not Done
Anti-Zo Yes No Not Available Not Done
Anti-CAM-140 Yes No Not Available Not Done
Anti-KS Yes No Not Available Not Done
Anti-HA Yes No Not Available Not Done
Anti-ZA Yes No Not Available Not Done
Other MSA / MAA Yes No Not Available Not Done
C. Treatments
Medication given prior to diagnosis of myositis and registration into database: Yes No
If yes, medications given: 
Steroid Yes No Not Available Not Recorded
Methotrexate / other DMARD Yes No Not Available Not Recorded
(Disease modifying anti-rheumatic 
drug)
Previous biologic Yes No Not Available Not Recorded
If yes to steroid: Oral Intravenous Topical Intramuscular
5. Diagnostic Investigations
Figure 2 Provisional JDM minimal dataset Form A, (first data entry only), page 2 – diagnostic investigations and treatments.
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use that can also inform research.
The development of an internationally agreed minimal
dataset could have numerous potential benefits. Unifica-
tion of data collection internationally will significantly
enhance collaborative efforts and communication be-
tween groups (whilst respecting data protection/owner-
ship) and allow analysis to be undertaken on the largest
possible number of JDM patients. This has the potentialto improve understanding of disease phenotype and out-
come in a way that will define research questions and
underpin prioritisation of future clinical trials. Analysis
of a large number of JDM patients with international
collaboration has the potential to help answer funda-
mental questions including characteristics of patients
who develop JDM, how patients develop the disease,
time to diagnosis (and raise awareness leading to quicker
diagnosis), which tests are most useful for diagnosis and
Provisional JDM Minimal Dataset, Form B: prospective data entry
Instructions on use / definitions available as supplementary material. 
For variables that are not available at time of data entry, but will be available at a later date, mark ‘not available’ (so that 
they can be chased and added at a later date). 
For variables that have not been examined / investigated, mark ‘not recorded’. 
*Details of patient ID to be completed / omitted as per local ethics / legal requirements. 
Patient ID Number* Patient Name*
Patient Consultant
/ Lead Clinician
Patient Hospital
and country
Date of form completion
A. Growth
Height (cm) Weight (kg)
B. Disease activity / damage (clinical features)
1. Active Muscle Disease
Proximal muscle weakness Yes No Not Available Not Done
Other muscle weakness Yes No Not Available Not Done
CMAS Score _______ Not Available Not Done
MMT8 Score _______ Not Available Not Done
2. Active Skin Disease
Heliotrope rash Yes No Not Available Not Done
Gottron’s Papules or Gottron’s sign Yes No Not Available Not Done
Nailfold capillary changes Yes No Not Available Not Done
Lipodystrophy Yes No Not Available Not Done
Calcinosis Yes No Not Available Not Done
Cutaneous ulceration due to myositis Yes No Not Available Not Done
Subcutaneous oedema due to myositis
Generalised Yes No Not Available Not Done
Peri-orbital Yes No Not Available Not Done
Other skin changes
Malar / facial erythema due to myositis Yes No Not Available Not Done
Shawl sign / V sign due to myositis Yes No Not Available Not Done
Mechanic’s hands Yes No Not Available Not Done
Alopecia due to myositis Yes No Not Available Not Done
Vasculopathic lesions due to myositis Yes No Not Available Not Done
Photosensitivity due to myositis Yes No Not Available Not Done
Livido reticularis due to myositis Yes No Not Available Not Done
Other erythema due to myositis Yes No Not Available Not Done
Panniculitis due to myositis Yes No Not Available Not Done
Figure 3 Provisional JDM minimal dataset, Form B, (prospective data collection), page 1 – disease activity and damage.
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creasingly, distinct clinical subtypes are recognised
within IIM, associated with myositis specific antibodies,
but differences are seen in adults and children [25]. Our
understanding of the mechanisms that underlie these
differences is limited by lack of studies directly compar-
ing adults and children in sufficient numbers. A minimal
dataset including disease characteristics and antibody
profiling may help to answer these questions with the
potential of directing subsequent clinical trials of treat-
ment strategies on disease stratified by serology. It is in-
creasingly recognized that patient reported perspectives
reveal disease aspects not covered by traditional out-
comes in myositis [26]. A minimal dataset will include
patient/parent reported outcome measures and work is
ongoing to develop new JDM-specific patient/reportedoutcome measures (the Juvenile Dermatomyositis Multi-
dimensional Assessment Report, JDMAR) [27]. With
international collaboration, patient reported outcome
measures, such as this, could be evaluated in large num-
bers of patients, helping to predict effectiveness for their
use in future clinical trials.
A large international collection has the potential to allow
detailed evaluation of ‘real world’ treatment interventions
used in clinical practice – based on clinician’s intention to
treat, to see if one treatment is better than another. The
CARRA database includes the option of clinicians choosing
which of a predefined number of treatment strategies to
use within the context of a consensus treatment plan [28].
If other studies contain the same minimal dataset, outcome
of patients on different treatments can be compared and
evaluated.
If yes: Dysphonia Yes No Not Available Not Done
If yes: Abdominal pain or GI ulceration due to 
myositis (exclude peptic ulcer disease) Yes No Not Available Not Done
Pulmonary involvement due to myositis –
interstitial lung disease Yes No Not Available Not Done
Cardiac involvement due to myositis Yes No Not Available Not Done
4. Constitutional
Fever (>38oC) due to myositis Yes No Not Available Not Done
Weight loss (>5%) due to myositis Yes No Not Available Not Done
Fatigue due to myositis Yes No Not Available Not Done
Irritability due to myositis Yes No Not Available Not Done
Raynaud’s phenomenon Yes No Not Available Not Done
5. Other
Malignancy Yes No Not Available Not Recorded
C. Is patient having on-going follow up at this centre after 
this date? Yes No
If no, reason why: Death Yes No
Transfer to another geographical area Yes No
Transfer to adult care
Patient in stable remission
Yes
Yes
No
No
D. Global disease activity
1. Physician VAS – global activity (overall) Not Available Not Done
Value: ___________________(range 0.0-10.0cm)
2. Physician VAS – extra-muscular global activity Not Available Not Done
Value: _____________________(range 0.0-10.0cm)
3. Parental / patient VAS Not Available Not Done
Value: _____________________(range 0.0-10.0cm) _
E. Health Questionnaires
CHAQ
(range  
0 - 3)
Not Available Not Done Value ____________________________
QoL Tool
(Exact tool to be determined by consensus) 
QoL Tool used Yes No Not Available
Name of QoL Tool used Score
3. Major organ involvement due to myositis
Musculoskeletal involvement due to myositis Yes No Not Available Not Done
If yes: Arthritis Yes No Not Available Not Done
If yes: Contractures due to myositis  Yes No Not Available Not Done
Gastrointestinal involvement due to myositis Yes No Not Available Not Done
If yes: Dysphagia Yes No Not Available Not Done
Figure 4 Provisional JDM minimal dataset, Form B, (prospective data collection), page 2 –disease activity/damage (continued).
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comparative studies of differences between adult and ju-
venile dermatomyositis. Our group has collaborated with
Euromyositis to produce a paediatric specific web pagefor data entry for patients with JDM (www.euromyositis.
eu). This web-page complements current data collection
on adult myositis and will allow comparison between the
two groups. New variables that are proposed as part of
F. Investigations
1. Blood tests- muscle enzyme elevation
CK Yes No Not Available Not Done
LDH Yes No Not Available Not Done
Adolase Yes No Not Available Not Done
AST/SGOT Yes No Not Available Not Done
ALT/SGPT Yes No Not Available Not Done
2. Abnormal investigation since last visit (consistent with flare of myositis)
MRI Yes No Not Available Not Done
Muscle biopsy Yes No Not Available Not Done
EMG Yes No Not Available Not Done
Lung function tests Yes No Not Available Not Done
ECG / ECHO Yes No Not Available Not Done
G. Treatment
1. Treatment start date (mm/yyyy) ______/_______ Not Available Not Recorded
2. Medication
Steroids Yes No Not Available Not Recorded
If yes to steroid: Oral Intravenous Topical Intramuscular
Methotrexate Yes No Not Available Not Recorded
Ciclosporin A Yes No Not Available Not Recorded
Mycophenolate Mofetil Yes No Not Available Not Recorded
Azathioprine Yes No Not Available Not Recorded
Hydroxychloroquine Yes No Not Available Not Recorded
Leflunamide Yes No Not Available Not Recorded
Cyclophosphamide Yes No Not Available Not Recorded
Rituximab Yes No Not Available Not Recorded
Etanercept Yes No Not Available Not Recorded
Infliximab Yes No Not Available Not Recorded
Adalimumab Yes No Not Available Not Recorded
IVIG Yes No Not Available Not Recorded
Plasmaphoresis Yes No Not Available Not Recorded
Topical steroid Yes No Not Available Not Recorded
Topical tacrolimus Yes No Not Available Not Recorded
Other Treatment: _________________________________________________________
3. Physiotherapy Yes No Not Available Not Recorded
Figure 5 Provisional JDM minimal dataset, Form B, (prospective data collection), page 3 – investigations and treatment.
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into the Euromyositis data collection. An important part
of this collaboration is to ensure that children entered
into adult networks have paediatric-specific outcomes
(such as growth) recorded. Collaborative efforts in
JDM have led to data-driven approaches such as re-
cently published PRINTO-driven criteria for defining
clinically inactive disease in JDM [29]. A minimal data-
set will allow validation of such approaches in large co-
horts of patients across several prospective data
collections.
A minimal dataset will provide a framework within
which all children with JDM can be monitored in a simi-
lar way, including important variables, as a minimum
standard of care. The dataset will prompt clinicians tocheck important clinical features including muscle
strength, skin activity and investigations each time a
child with JDM is seen. This is important since JDM is a
rare disease and some clinicians are not seeing large
numbers of patients with the disease. The importance of
defining minimal standards of care has been recognized
internationally and members of our group are involved
in a European effort to produce standards of care within
a Single Hub and Access Point for Paediatric Rheuma-
tology in Europe (SHARE) for JDM as well as other
paediatric rheumatological conditions [30].
A provisional minimal dataset has been defined by con-
sensus between a group of experts in JDM, representative
of the major national and international JDM collaborative
efforts. This now needs to be refined and tested for its
McCann et al. Pediatric Rheumatology 2014, 12:31 Page 10 of 11
http://www.ped-rheum.com/content/12/1/31usefulness and acceptability in a wider international set-
ting. In order to achieve this, a formal consensus-driven
methodology is required of all stakeholders. This will in-
clude a Delphi process to gain widespread opinion via the
established JDM networks that will help to inform a more
detailed face-to-face nominal group consensus process by
internationally representative JDM experts.
Conclusion
JDM is a rare but serious inflammatory condition with an
appreciable risk of long-term morbidity. There are many
unanswered questions around epidemiology, pathogenesis,
treatment and outcome of the disease. The provisional
dataset developed to date will be used as a template to aid
a formal multi-stage consensus process, involving large
groups of clinicians caring for children with JDM, with the
aim of developing a feasible, internationally agreed min-
imal dataset for clinical use that can inform research.
Additional file
Additional file 1: Form A: provisional definitions, Form B:
provisional definitions (to be refined further as part of on-going
work) [31-37].
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